All News
Apremilast Succeeds in Scalp Psoriasis
Celgene has announced results from the phase 3 STYLE study, showing apremilast yielding significant improvement in moderate-to-severe scalp psoriasis. STYLE is a phase 3, multicenter, randomized, placebo-controlled, double-blind study evaluating the efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis of the scalp. The study enrolled 303 people who were randomized 2:1 to receive apremilast 30 mg twice daily or placebo for the first 16 weeks.
Read ArticleTeenage Obesity Increases Lupus Risk
Analysis of the Black Women's Health Study shows that obesity as a teenager may be associated with increased risk of systemic lupus erythematous (SLE) in adulthood.
Read ArticlePhysical Therapy Equals Arthroscopic Surgery in Meniscal Tears
Several new trials suggest that conservative management may be as efficacious as arthroscopic surgery in patients with meniscal tears, thus contributing to the trend of fewer arthroscopic surgeries. A new trial of patients with nonobstructive meniscal tears shows no significant difference in 2 year outcomes between physical therapy and early arthroscopic partial meniscectomy.
Allopurinol Shown to be Renal Protective
Neogi and colleagues have shown that standard doses of allopurinol (300 mg/day) were associated with a 13% lower risk of renal function deterioration in chronic gout patients - thus, allopurinol does not appear to impair renal function over time.
Read ArticleAnxiety and Depression are Common in Arthritis Patients
The high prevalence of symptoms of anxiety and depression among adults with arthritis warrants awareness, screening, and subsequent treatment of these conditions.
Read ArticleVitamin D Fails to Improve Bone Health
The current edition of Lancet Diabetes & Endocrinology suggests that neither vitamin D supplementation, nor dose, will improve bone density or prevent fractures in adults.
Read ArticleActivity Trackers May be Helpful in Arthritis Patients
Use of wearable activity trackers was associated with increases in the number of daily steps among individuals with rheumatic and musculoskeletal disorders, a meta-analysis found.
Read ArticlePredictive Risk Factors for Uveitis in JIA
Researchers from Germany have studied a large cohort of juvenile idiopathic arthritis (JIA) patients and shown that JIA disease activity scores and laboratory biomarkers could be used to better define the group of JIA patients at high risk of uveitis onset.
Read ArticleZolendronic Acid Benefits Elder Women with Osteopenia
The NEJM reports that zolendronic acid was shown to significantly lower the risk of nonvertebral or vertebral fragility fractures in older women with osteopenia.
Read ArticleExcess Mortality in CTD or Systemic Vasculitis Patients
The Norwegian connective tissue disease (CTD) and systemic vasculitis (PSV) registry (NOSVAR) studied patient outcomes over a 15 year period and found overall mortality to be higher in the CTD compared to the PSV group.
Read ArticleDoes Gender Make a Difference in Axial Spondyloarthritis
Males and females can both be affected by axial spondyloarthritis (axSpA). A recent study shows that while there are some differences and similarities, HLA-B27 and imaging are still pivotal elements for diagnosis of axSpA in both genders.
Read ArticleLong-Term Efficacy of Canakinumab in Systemic Juvenile Idiopathic Arthritis
Only inhibitors of IL-1 (canakinumab) and IL-6 (tocilizumab) are FDA approved for use in children with systemic onset juvenile idiopathic arthritis (sJIA). Now, long-term data from the extension studies from two phase III studies shows that canakinumab yields long-term improvements with reduced glucocorticoid dosing with no new safety findings with long-term use.
Read ArticleNeuropathic Like Knee Pain
Fernandez and colleagues have shed further light on a significant subset of patients with knee pain - specifically, those with neuropathic like knee pain (NKP) that includes those with knee pain modified by central and peripheral neurologic dysfunction.
Read ArticleVenous Thromboembolism Increased with Rheumatoid Arthritis, Not with TNF Inhibition
Venous thromboembolism (VTE) is a common adverse event throughout medicine and includes both pulmonary embolism (PE) and deep vein thrombosis (DVT). The cost of diagnosing a thromboembolic event is approximately $4000 - $5550, while the annual cost of treating one case of VTE is betwe
Read ArticleCDC: 2017 Record Number of Influenza Deaths
The CDC reports that in 2017, influenza killed and hospitalized more people in the United States than any other year in the last few decades.
Read ArticleMortality Improves in Lupus ESRD
The past two decades have seen a significant decline in mortality among patients with lupus nephritis, U.S. registry data indicated.
Read ArticleKnee Arthroscopic Surgeries on the Decline
A JAMA Internal Medicine report has shown that the rate of arthroscopic surgery has significantly declined, in an era when arthroplasty and the incidence of osteoarthritis (OA) has increased.
Read ArticleFractures May Lead to Systemic Bone Loss
Researchers at the University of California - Davis have shown that elderly women who had an upper body fracture or multiple fractures had more loss of hip density compared to those who who did not fracture. Systemic bone loss may increase the risk of future fractures.
Read ArticleMaastricht Study Links Dairy Intake to Osteoarthritis
The Maastricht study explored the potential association between dairy consumption and knee osteoarthritis (OA), and found that higher intake of full-fat dairy and Dutch cheese - but not milk - was significantly associated with the lower risk of knee OA.
Read ArticleQuarterly Canakinumab Reduces Gout Risk Without Affecting Uric Acid
The Annals of Internal Medicine reports that interleukin-1 (IL-1) inhibitor treatment is associated with a reduced risk of gout attacks - such are the findings of an anlysis of the CANTOS study previously reported at the Annual ACR 2017 meeting in Washington, DC.
Read Article


